Cervical cancer ranks as the fourth most prevalent cancer among women, and the seventh most common cancer. According to the Agency for Research on Cancer (IARC) database [1], in 2020, there were approximately 604,000 global cases of cervical cancer and 341,000 related deaths. Additionally, existing chemotherapeutic agents show only modest efficacy against recurrent disease. Therefore, there is a continued need for new therapeutic approaches for advanced and recurrent cervical cancers.
Kagabu, Masahiro, et al. (2023) examined oncolytic HSV therapy with anti-PD-L1 Ab for cervical cancer, focusing on the oncolytic herpes virus (T-01) antitumour effect of an ICI in a bilateral tumour model. Since TC-1 cells express the HPV E7 tumour antigen, CD8 T cells against TC-1 were analysed by tetramer assay using glycoprotein B (gB), one of the HSV envelope proteins. The tumour tissues were stained with (PE)-labelled HPV16 E7 tetramer or PE-labelled HSV gB tetramer. The data indicated the treatment combination group had increased E7-specific CD8+ T-cells compared with the T-01 group. In addition, the T-01 group showed increased E7-specific CD8+ T-cells compared with those of the PD-L1 Ab group (1).
Overall the study by Kagabu, Masahiro, et al. (2023) that T-01 showed a cytotoxic impact on stimulated T cells, indicating that the interaction between T-01 and anti-PD-L1 Ab may potentially have an antagonistic impact. Therefore, it is advised to proceed with caution when using simultaneous administration.
References:
(1)Kagabu, Masahiro, et al. “Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor.” International Journal of Molecular Sciences 24.3 (2023): 1988.
Information provided by MBL.
Caltag Medsystems is the distributor of MBL products in the UK and Ireland. If you have any questions about these products, please contact us.